When ZymoGenetics Inc. decided it would develop recombinant human thrombin (rhThrombin; Recothrom) as the first product it would keep for itself, there was only one competitor on the market: Thrombin-JMI, a bovine thrombin approved in 1995 and sold by King Pharmaceuticals Inc.Johnson & Johnson had stopped selling its bovine thrombin in 1999, the threat of mad cow disease had closed off the European market, and JMI’s label had carried a boxed warning since 1996 about the severe bleeding risks associated with potential antibody formation.
To that point, the biotech had out-licensed its development programs, including a broad deal with Serono (now Merck Serono...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?